<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179643</url>
  </required_header>
  <id_info>
    <org_study_id>NAN-CS101</org_study_id>
    <nct_id>NCT04179643</nct_id>
  </id_info>
  <brief_title>NAN-101 in Patients With Class III Heart Failure</brief_title>
  <acronym>NAN-CS101</acronym>
  <official_title>Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios Biopharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asklepios Biopharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to&#xD;
      explore the safety, feasibility, and efficacy of a single intracoronary infusion of&#xD;
      BNP116.sc-CMV.I1c in patients with NYHA Class III heart failure. Patients with symptomatic&#xD;
      congestive heart failure will be enrolled until up to 12 subjects have received infusions of&#xD;
      investigational product. All patients will be followed until 12 months post treatment&#xD;
      intervention, and then undergo long-term follow-up via semi-structured telephone&#xD;
      questionnaires every 6 months for an additional 24 months (+/- 30 days).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint for this study is safety as measured by the following which will be&#xD;
      assessed over the 12 month follow-up period as indicated in the Data Collection Table:&#xD;
&#xD;
        -  Adverse Events&#xD;
&#xD;
        -  All-cause Mortality&#xD;
&#xD;
        -  Heart failure (HF) Hospitalization&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
      The secondary safety endpoints assessed will include the following:&#xD;
&#xD;
        -  Echocardiographic assessments at 4 weeks +/- 3 days post-administration of&#xD;
           BNP116.sc-CMV.I1c including&#xD;
&#xD;
        -  Echocardiographic assessments of LVEF, LVEVD, LVEDVI, VLESV, LVEVI, SpI and GLSand&#xD;
           degree of mitral regurgitation o&#xD;
&#xD;
      The secondary efficacy endpoints will explore efficacy. Functional endpoints will be assessed&#xD;
      as changes from baseline to 6 and 12 months following investigational product administration&#xD;
      as indicated. These endpoints include:&#xD;
&#xD;
      Functional Status &amp; Hospitalizations&#xD;
&#xD;
        -  Peak VO2 assessed by cardiopulmonary exercise testing&#xD;
&#xD;
        -  6-minute walk test&#xD;
&#xD;
        -  New York Heart Association (NYHA) Classification&#xD;
&#xD;
        -  Total number of days alive out-of-hospital (as well as total days out-of-hospital as a %&#xD;
           of total days alive post study intervention)&#xD;
&#xD;
      Physiologic Assessments at 6 and 12 months compared to baseline&#xD;
&#xD;
        -  Echocardiographic assessments of LVEF, LVEVD, LVEDVI, VLESV, LVEVI, SpI and GLSand&#xD;
           degree of mitral regurgitation&#xD;
&#xD;
        -  NT-proBNP level&#xD;
&#xD;
      Quality of Life at 6 and 12 months compared to baseline&#xD;
&#xD;
      o Health related quality of life as assessed by Minnesota Living with Heart Failure&#xD;
      Questionnaire (MLWHFQ)&#xD;
&#xD;
      The following endpoints will also be measured over the 12 month follow-up period and&#xD;
      long-term follow-up period (until month 36 post-intervention):&#xD;
&#xD;
        -  Survival&#xD;
&#xD;
        -  Cardiac transplantation&#xD;
&#xD;
        -  Left ventricular assist device (LVAD) implantation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed and change from baseline in Peak VO2</measure>
    <time_frame>Measured at screening, month 6 and month 12</time_frame>
    <description>Cardiopulmonary exercise testing using a modified Bruce protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed and change from baseline in Echocardiographic assessment in Left Ventricular Ejection Fraction</measure>
    <time_frame>Measured at screening, 18-24 hours post intervention, week 4, Month 6 and Month 12</time_frame>
    <description>Echocardiography LVEF measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed and change from baseline in 6-minute walk test distance</measure>
    <time_frame>Measured at screening, Month 6 and month 12</time_frame>
    <description>Analysis of Percent predicted in heart failure subjects compared to normal subjects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Heart Failure</condition>
  <condition>Heart Disease, Ischemic</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Failure, Systolic</condition>
  <condition>Heart Failure，Congestive</condition>
  <condition>Heart Arrhythmia</condition>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Heart; Complications</condition>
  <arm_group>
    <arm_group_label>3 x 10e13vg NAN-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary Infusion of NAN-101 at 3 x 10e13vg up to 4 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 x 10e14vg NAN-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary Infusion of NAN-101 1 x 10e14vg up to 4 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 x 10e14 vg NAN-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary Infusion of NAN-101 3 x 10e14 vg up to 4 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3 x 10e13vg NAN-101</intervention_name>
    <description>There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.</description>
    <arm_group_label>1 x 10e14vg NAN-101</arm_group_label>
    <arm_group_label>3 x 10e13vg NAN-101</arm_group_label>
    <arm_group_label>3 x 10e14 vg NAN-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age &gt;18 years of age&#xD;
&#xD;
          -  Chronic non-ischemic cardiomyopathy&#xD;
&#xD;
          -  LVEF ≤ 30% by transthoracic echocardiography (TTE) within 6 months prior to enrollment&#xD;
&#xD;
          -  NYHA Class III HF for a minimum of 6 months HF despite appropriate medical therapy&#xD;
             (defined below):&#xD;
&#xD;
               -  Treatment with appropriate HF therapy as tolerated, including, but not limited&#xD;
                  to:&#xD;
&#xD;
               -  Beta blocker therapy and angiotensin converting enzyme (ACE) inhibitor or&#xD;
                  angiotensin receptor blocker (ARB) or sacubitril/valsartan combination therapy&#xD;
                  (Entresto) for ≥ 90 days prior to enrollment. May also receive aldosterone&#xD;
                  antagonist therapy. Doses of the above medications must be stable for ≥ 30 days&#xD;
                  prior to enrollment; and&#xD;
&#xD;
               -  Cardiac resynchronization therapy (CRT), if clinically indicated, must have been&#xD;
                  implanted ≥ 90 days prior to enrollment. Internal cardioverter defibrillator&#xD;
                  (ICD) must be implanted, if clinically indicated ≥ 30 days prior to enrollment&#xD;
&#xD;
          -  Females of childbearing potential must use at least one of the following acceptable&#xD;
             birth control methods throughout the study and for 6 months after IP administration:&#xD;
&#xD;
          -  Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6&#xD;
             months minimum prior to IP administration&#xD;
&#xD;
          -  Intrauterine device in place for at least 90 days prior to receiving IP&#xD;
&#xD;
          -  Barrier methods (diaphragm plus spermicide or condom) starting at least 30 days prior&#xD;
             to receiving IP&#xD;
&#xD;
          -  Abstinence (the subject must be willing to remain abstinent from screening to 6 months&#xD;
             after receiving IP). Females are allowed to claim abstinence as their method of&#xD;
             contraception only when it is the preferred and usual lifestyle of the subject&#xD;
&#xD;
          -  Surgical sterilization of the partner(s) (vasectomy) for &gt;180 days prior to IP&#xD;
             administration&#xD;
&#xD;
          -  Hormonal contraceptives starting &gt; 90 days prior to IP. If hormonal contraceptives are&#xD;
             started less than 90 days prior to receiving IP, subjects must agree to use a barrier&#xD;
             method (diaphragm plus spermicide or condom) from screening through 90 days after&#xD;
             initiation of hormonal contraceptives&#xD;
&#xD;
          -  Males subjects capable of fathering a child:&#xD;
&#xD;
          -  Must agree to use a condom from IP administration through 6 months after the time of&#xD;
             IP administration&#xD;
&#xD;
          -  Must agree not to donate sperm for 6 months after time of receiving IP&#xD;
&#xD;
          -  Documented evidence of vasectomy in males for 180 days minimum prior to receiving IP&#xD;
             is an acceptable form of contraception&#xD;
&#xD;
          -  Males who claim abstinence as their method of contraception are allowed provided they&#xD;
             agree to use barrier methods should they become sexually active from screening through&#xD;
             6 months after receiving IP. Males are allowed to claim abstinence as their method of&#xD;
             contraception only when it is the preferred and usual lifestyle of the subject&#xD;
&#xD;
          -  Ability to sign Informed Consent Form (ICF) and Release of Medical Information Form&#xD;
&#xD;
          -  Appropriate candidate for protocol-specified intracoronary infusion in the judgment of&#xD;
             the infusing interventional cardiologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic ischemic cardiomyopathy&#xD;
&#xD;
          -  Intravenous (IV) inotropic therapy, intra-aortic balloon pump (IABP) or percutaneous&#xD;
             cardiac assist device therapy within 30 days prior to enrollment&#xD;
&#xD;
          -  Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease,&#xD;
             amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic&#xD;
             LV aneurysm&#xD;
&#xD;
          -  Cardiac surgery or percutaneous coronary intervention (PCI) within 30 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Third degree heart block&#xD;
&#xD;
          -  Clinically significant myocardial infarction (MI) in the judgment of the subject's&#xD;
             physician (e.g., ST elevation MI [STEMI] or large non-STEMI) within 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Prior heart transplantation, left ventricular reduction surgery (LVRS),&#xD;
             cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device),&#xD;
             surgically implanted LVAD or cardiac shunt&#xD;
&#xD;
          -  Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LV reduction&#xD;
             surgery, heart transplant, conventional revascularization procedure, or valvular&#xD;
             repair within 3 months of IP dosing&#xD;
&#xD;
          -  Known hypersensitivity to contrast dyes used for angiography; history of, or likely&#xD;
             need for, high-dose steroid pretreatment prior to contrast angiography&#xD;
&#xD;
          -  Expected survival &lt; 1 year in the judgment of the investigator&#xD;
&#xD;
          -  Active or suspected infection within 48 hours prior to enrollment as evidenced by&#xD;
             fever or positive culture&#xD;
&#xD;
          -  Known intrinsic liver disease (e.g., cirrhosis, hepatitis A, chronic hepatitis B or&#xD;
             hepatitis C virus infection). If serology is positive and PCR is negative, subject may&#xD;
             be eligible (confirm with medical monitor).&#xD;
&#xD;
          -  Liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase&#xD;
             [AST], alkaline phosphatase) &gt; 2x upper limit of normal (ULN) within 30 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Renal Failure, dialysis dependent or serum creatinine &gt; 2.5 mg/dl within 30 days prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Bleeding diathesis or thrombocytopenia defined as platelets &lt;50,000 platelets/μL&#xD;
             within 30 days prior to enrollment&#xD;
&#xD;
          -  Anemia defined as hemoglobin &lt;10 g/dL or transfusion dependent within 30 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Neutropenia defined as absolute neutrophils &lt;1500 mm3 within 30 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Known AIDS or HIV-positive status, or a previous diagnosis of immunodeficiency with an&#xD;
             absolute neutrophil count &lt;1000 cells/mm3&#xD;
&#xD;
          -  Previous participation in a study of gene transfer&#xD;
&#xD;
          -  Receiving investigational intervention or participating in another clinical study&#xD;
             within 30 days or within 5 half-lives of another investigational drug administration&#xD;
             prior to administration of NAN-101 that may impact the therapeutic potential of&#xD;
             NAN-101.&#xD;
&#xD;
          -  Pregnancy or breastfeeding at the time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Minneapolis Heart Foundation Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake Jensen</last_name>
      <phone>612-863-3818</phone>
      <email>jacob.jensen@allina.com</email>
    </contact>
    <investigator>
      <last_name>Jay Traverse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Linder Center for Education and Research at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Krabbe, RN</last_name>
      <phone>513-585-1790</phone>
      <email>dkrabbe@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Timothy D Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shawna Oxier, RN</last_name>
      <phone>614-247-6797</phone>
      <email>shawna.oxier@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Boudoulas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin at Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

